Publicaciones (20) Publicaciones de Guadalupe Rivero Calera Ver datos de investigación referenciados.

2024

  1. Effect of antipsychotic drugs on group II metabotropic glutamate receptor expression and epigenetic control in postmortem brains of schizophrenia subjects

    Translational Psychiatry, Vol. 14, Núm. 1

  2. Permissive epigenetic regulatory mechanisms at the histone level are enhanced in postmortem dorsolateral prefrontal cortex of individuals with schizophrenia

    Journal of Psychiatry and Neuroscience, Vol. 49, Núm. 1, pp. E35-E44

  3. Sex differences in neural projections of fear memory processing in mice and humans

    Science Advances, Vol. 10, Núm. 28

2023

  1. GRM2 eta GRM3 geneen adierazpenaren ebaluazioa subjektu eskizofrenikoen postmortem garuneko kortex aurrefrontalean

    Osasun zientziak: V. Ikergazte Nazioarteko Ikerteta Euskaraz. 2023eko maitzaren 17, 18 eta 19 Donostia, Euskal Herria.

2021

  1. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Epigenetika helburu duten sendagaiak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 40, pp. 11-31

  3. Giza garun postmortemeko nukleo neuronalen eta ez-neuronalen banaketa

    Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.

  4. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

    Translational Psychiatry, Vol. 11, Núm. 1

2016

  1. Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence

    World Journal of Biological Psychiatry, Vol. 17, Núm. 4, pp. 308-315

2015

  1. Up-regulated 14-3-3β and 14-3-3ζ proteins in prefrontal cortex of subjects with schizophrenia: Effect of psychotropic treatment

    Schizophrenia Research, Vol. 161, Núm. 2-3, pp. 446-451

2014

  1. Increased α2- and β1-adrenoceptor densities in postmortem brain of subjects with depression: Differential effect of antidepressant treatment

    Journal of Affective Disorders, Vol. 167, pp. 343-350

2013

  1. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment

    Psychopharmacology, Vol. 226, Núm. 1, pp. 177-188

  2. Ethanol reversal of cellular tolerance to morphine in rat locus coeruleus neurons

    Molecular Pharmacology, Vol. 84, Núm. 2, pp. 252-260

2012

  1. Differential regulation of RGS proteins in the prefrontal cortex of short- and long-term human opiate abusers

    Neuropharmacology, Vol. 62, Núm. 2, pp. 1044-1051

  2. Endomorphin-2: A biased agonist at the μ-opioid receptor

    Molecular Pharmacology, Vol. 82, Núm. 2, pp. 178-188

2010

  1. Characterization of regulators of G-protein signaling RGS4 and RGS10 proteins in the postmortem human brain

    Neurochemistry International, Vol. 57, Núm. 7, pp. 722-729

  2. Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization

    European Journal of Pharmacology, Vol. 649, Núm. 1-3, pp. 29-37

  3. μ-opioid receptors: Correlation of agonist efficacy for signalling with ability to activate internalization

    Molecular Pharmacology, Vol. 78, Núm. 4, pp. 756-766

2008

  1. Regulation of the extrinsic and intrinsic apoptotic pathways in the prefrontal cortex of short- and long-term human opiate abusers

    Neuroscience, Vol. 157, Núm. 1, pp. 105-119

2006

  1. The N251K functional polymorphism in the α2A-adrenoceptor gene is not associated with depression: A study in suicide completers

    Psychopharmacology, Vol. 184, Núm. 1, pp. 82-86